Wockhardt Limited files SEBI Regulation 31(4) disclosure on substantial acquisition
Wockhardt Limited, a listed pharmaceutical company, has submitted a disclosure under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 to the National Stock Exchange. This disclosure is mandatory when a party acquires 25% or more of voting capital, or has already acquired 25% and acquires a further 2% in any financial year (creeping acquisition). The filing does not specify the acquirer, consideration, or shareholding threshold crossed based on the article excerpt; the full details are contained in the NSE-filed PDF document dated 30 June 2026.
Why it mattersRegulation 31(4) disclosure signals either a trigger of the 25% threshold requiring an open offer, or a concert-party or creeping acquisition requiring regulatory notification-partner must obtain the full disclosure document to determine acquirer identity, price, shareholding crossed, and open offer timeline obligations.
SectorPharma & Healthcare
[object Object][object Object][object Object][object Object][object Object][object Object][object Object][object Object]
Sources
- NSE Archives - Wockhardt Limited Disclosure Filing · official
- SEBI - Takeover Regulations Portal · official
- NSE - Corporate Actions & Disclosures Portal · official
- BSE corporate announcements · official
- NSE corporate announcements · official
- CCI combination orders · official
Related deals
- Anupam Rasayan India acquires controlling stake in Bliss GVS Pharma; Kanga & Co advises sellers28 Oct 2026
- Fortis Healthcare Limited: Press Release28 Oct 2026 · ₹277 Cr
- Fortis Healthcare Limited: Acquisition28 Oct 2026
- ThinkLaw advises Jagsonpal Pharma on acquiring Group Pharma's wellness portfolio27 Oct 2026
- Mankind Pharma Limited: Scheme of Arrangement26 Oct 2026
- Mankind Pharma Limited: Scheme of Arrangement26 Oct 2026